Mumbai-based pharmaceutical giant Lupin Ltd has received a crucial regulatory nod from the U.S. Food and Drug Administration (USFDA) for its generic version of Prucalopride tablets, designed for the treatment of chronic idiopathic constipation (CIC) in adults. The approval covers two dosage strengths—1 mg and 2 mg—and positions Lupin to compete in a U.S. market segment estimated at $184 million annually, according to IQVIA MAT data for April 2025. The drug will be manufactured at Lupin’s state-of-the-art facility in Goa, bolstering the company’s global manufacturing capabilities and generics portfolio.
Expanding Access Through Generics
Lupin’s regulatory green light for Prucalopride tablets reflects the company’s continued emphasis on expanding access to affordable medication in the U.S. market. The product is the generic equivalent of Motegrity, a branded drug developed by Takeda Pharmaceuticals USA, and is indicated for adults suffering from chronic idiopathic constipation—a condition marked by persistent difficulty in bowel movements with no identifiable cause.
With this approval, Lupin not only adds another critical therapy area to its growing generics pipeline but also underscores its operational readiness to serve regulated markets with high-quality, cost-effective alternatives. The timing is particularly opportune given the increasing healthcare cost pressures and demand for generic options across the United States.
Manufactured in India, Marketed Globally
The Prucalopride tablets will be produced at Lupin’s manufacturing unit in Goa, a facility that has consistently passed international inspections and adheres to current Good Manufacturing Practice (cGMP) standards. This move reiterates India’s rising stature as a global pharmaceutical manufacturing hub, particularly for high-value generics aimed at North American and European markets.
Manufacturing in Goa allows Lupin to leverage economies of scale and operational efficiency, ensuring both affordability and quality compliance. The company’s integrated manufacturing model also strengthens its ability to respond quickly to market demand and regulatory expectations.
Targeting a Lucrative U.S. Segment
The U.S. chronic idiopathic constipation drug market represents a substantial commercial opportunity. IQVIA’s latest data pegs annual sales for Prucalopride tablets at approximately $184 million. Lupin’s entry into this space, especially with bioequivalent dosage forms, could drive significant cost savings for the healthcare system while allowing the company to tap into an expanding patient base.
CIC is a common gastrointestinal disorder affecting millions in the U.S., with many patients requiring long-term treatment. Lupin’s timely approval gives it first-mover advantage among new generic entrants and enhances its therapeutic reach in the gastroenterology segment.
Strengthening Global Competitiveness
Lupin’s growing portfolio of USFDA-approved generics reflects a well-calibrated international strategy rooted in innovation, regulatory excellence, and geographic diversification. The company continues to invest in complex generics and niche therapeutic areas while maintaining a competitive pricing model that appeals to healthcare providers and payers alike.
With over 70 U.S. ANDAs (Abbreviated New Drug Applications) already approved and several more in the pipeline, Lupin’s expanding U.S. presence speaks to its long-term ambition of becoming a leading player in the global generics landscape.
Conclusion: A Step Forward in Affordable Healthcare
This latest USFDA approval affirms Lupin’s role as a critical player in delivering cost-effective healthcare solutions on a global scale. By bringing high-quality, affordable generics like Prucalopride to the U.S. market, the company not only drives business growth but also contributes meaningfully to broader public health objectives.
As pricing pressures and access challenges persist across the pharmaceutical industry, Lupin’s strategic focus on regulated markets and therapeutic relevance ensures it remains at the forefront of delivering value-driven innovation.
Comments